Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

China flag China · Delayed Price · Currency is CNY
36.60
-0.35 (-0.95%)
Mar 9, 2026, 3:00 PM CST
37.67%
Market Cap 5.36B
Revenue (ttm) 448.37M
Net Income (ttm) 46.80M
Shares Out 146.32M
EPS (ttm) 0.32
PE Ratio 114.38
Forward PE n/a
Dividend 1.07 (2.90%)
Ex-Dividend Date n/a
Volume 2,221,100
Average Volume 2,878,290
Open 36.33
Previous Close 36.95
Day's Range 35.50 - 36.87
52-Week Range 22.51 - 50.98
Beta 0.57
RSI 48.37
Earnings Date Apr 25, 2026

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. In addition, the company is widely utilized across various medical institutions, judicial testing... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 622
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688767
Full Company Profile

Financial Performance

In 2025, Hangzhou Biotest Biotech's revenue was 448.37 million, a decrease of -19.85% compared to the previous year's 559.40 million. Earnings were 46.80 million, a decrease of -72.39%.

Financial Statements

News

There is no news available yet.